These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

70 related items for PubMed ID: 15384954

  • 1. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results.
    Reboussin DM, Goff DC, Lipkin EW, Herrington DM, Summerson J, Steffes M, Crouse RJ, Jovanovic L, Feinglos MN, Probstfield JL, Banerji MA, Pettitt DJ, Williamson J.
    Diabet Med; 2004 Oct; 21(10):1082-9. PubMed ID: 15384954
    [Abstract] [Full Text] [Related]

  • 2. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P.
    Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
    [Abstract] [Full Text] [Related]

  • 3. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.
    Davies MJ, Thaware PK, Tringham JR, Howe J, Jarvis J, Johnston V, Kitchener DL, Skinner TC, McNally PG, Lawrence IG.
    Diabet Med; 2007 Jul; 24(7):714-9. PubMed ID: 17403126
    [Abstract] [Full Text] [Related]

  • 4. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
    De Jager J, Kooy A, Lehert P, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD.
    J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 6. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP.
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [Abstract] [Full Text] [Related]

  • 7. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.
    Stewart MW, Cirkel DT, Furuseth K, Donaldson J, Biswas N, Starkie MG, Phenekos C, Hamann A.
    Diabet Med; 2006 Oct; 23(10):1069-78. PubMed ID: 16978370
    [Abstract] [Full Text] [Related]

  • 8. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G, Issa M, Vlajnic A.
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [Abstract] [Full Text] [Related]

  • 9. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 10. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].
    González-Ortiz M, Martínez-Abundis E, Grupo para el Tratamiento de la Diabetes Mellitus con Combinaciones.
    Rev Invest Clin; 2004 Oct; 56(3):327-33. PubMed ID: 15612515
    [Abstract] [Full Text] [Related]

  • 11. A comparison of costs for four oral antidiabetic regimens within a managed care population.
    Stockl K, Vanderplas AM, Nicklasson L.
    Manag Care Interface; 2003 Jul; 16(7):31-6. PubMed ID: 12908215
    [Abstract] [Full Text] [Related]

  • 12. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
    Shapiro MS, Abrams Z, Lieberman N.
    Isr Med Assoc J; 2005 Feb; 7(2):75-7. PubMed ID: 15729954
    [Abstract] [Full Text] [Related]

  • 13. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
    Jones MR, Mudaliar S, Hernandez-Triana E, Unnikrishnan AG, Lai YL, Abby SL, Misir S, Jin X, Nagendran S.
    Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 15. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin.
    Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M.
    Diabetes Care; 2006 Aug; 29(8):1818-25. PubMed ID: 16873786
    [Abstract] [Full Text] [Related]

  • 16. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA.
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [Abstract] [Full Text] [Related]

  • 17. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial.
    Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ, Metformin Trial Group.
    Diabet Med; 2005 May; 22(5):634-40. PubMed ID: 15842521
    [Abstract] [Full Text] [Related]

  • 18. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
    Yngen M, Ostenson CG, Hjemdahl P, Wallén NH.
    Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
    [Abstract] [Full Text] [Related]

  • 19. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
    Davidson JA, Perez A, Zhang J, Pioglitazone 343 Study Group.
    Diabetes Obes Metab; 2006 Mar; 8(2):164-74. PubMed ID: 16448520
    [Abstract] [Full Text] [Related]

  • 20. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
    Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.